thats ridiculous..at asco they will be only giving dosing for the phase 11 for 113 and info we all know regarding ponatinib..all im saying is that at a 2 billion valuation in a so so market it would be fairly valued..the real info for 113 will be in october and into next year.
dont get me wrong..ponatinib is the real deal and the market had priced it in prior to approval..113 will be the next real catalyst..but that is close to a year away.
will it bounce into asco..probably..could it trade back to 18-19..sure it can.
but as you look a little longer term i think we can see a 2 billion mkt cap(11 per share) over the summer...and yes it may be a great buy at those levels.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.